Literature DB >> 15564288

Polymorphisms in XPD and TP53 and mutation in human lung cancer.

Leah E Mechanic1, Aizen J Marrogi, Judith A Welsh, Elise D Bowman, Mohammed A Khan, Lindsey Enewold, Yun-Ling Zheng, Stephen Chanock, Peter G Shields, Curtis C Harris.   

Abstract

The pattern of somatic mutations in TP53 is distinct for particular cancers and carcinogenic exposures, providing clues to disease etiology, e.g. G:C-->T:A mutations in TP53 are more frequently observed in smoking-associated lung cancers. In order to investigate possible causes and mechanisms of lung cancer susceptibility differences, the TP53 gene was sequenced in a case-only study of lung cancers (206 men and 103 women). Our primary hypothesis was that the TP53 mutation spectrum is influenced by polymorphisms in genes involved in DNA repair and apoptosis. We observed a TP53 mutation frequency in exons 5-8 of 25%. Functional polymorphisms in XPD (Asp312Asn, rs1799793 and Lys751Gln, rs1052559), a protein required for nucleotide excision repair and with roles in p53-mediated apoptosis, were modestly associated with G:C-->T:A mutations in TP53 in lung tumors [Asp/Asn312 + Asn/Asn312 and/or Lys/Gln751 + Gln/Gln751 versus Asp/Asp312 + Lys/Lys751; odds ratio (OR) 2.73, 95% confidence interval (CI) 0.98-7.61], consistent with the role of this protein in repair of bulky carcinogen-DNA adducts. In addition, a TP53 polymorphism (Arg72Pro, rs1042522) with a known role in the efficiency of apoptosis was also associated with the presence of a TP53 mutation (Pro/Arg72 or Pro/Pro72 versus Arg/Arg72; OR 2.25, 95% CI 1.21-4.17) or a G:C-->T:A mutation in TP53 (Pro/Arg72 or Pro/Pro72 versus Arg/Arg72; OR 2.42, 95% CI 0.97-6.04). An interaction between the XPD variant alleles (Asn312 and Gln751) and the TP53 Pro72 allele was observed for TP53 mutations (any TP53 mutation P(int) = 0.027, G:C-->T:A TP53 mutation P(int) = 0.041). The statistical interaction observed in our study is consistent with the observed biological interaction for XPD and p53 in nucleotide excision repair and apoptosis. In conclusion, differences in TP53 mutation spectra in lung tumors are associated with several genetic factors and may reflect differences in lung cancer susceptibility and carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564288     DOI: 10.1093/carcin/bgh344

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  15 in total

1.  Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women.

Authors:  Susan E Olivo-Marston; Leah E Mechanic; Steen Mollerup; Elise D Bowman; Alan T Remaley; Michele R Forman; Vidar Skaug; Yun-Ling Zheng; Aage Haugen; Curtis C Harris
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

2.  p53 Pro72Arg polymorphism and prostate cancer in men of African descent.

Authors:  L Ricks-Santi; T Mason; V Apprey; C Ahaghotu; A McLauchlin; D Josey; G Bonney; G M Dunston
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

3.  Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer.

Authors:  R K Gill; S-H Yang; D Meerzaman; L E Mechanic; E D Bowman; H-S Jeon; S Roy Chowdhuri; A Shakoori; T Dracheva; K-M Hong; J Fukuoka; J-H Zhang; C C Harris; J Jen
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

Review 4.  Clinical outcomes and correlates of TP53 mutations and cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

Review 5.  Genetic variation in microRNA networks: the implications for cancer research.

Authors:  Bríd M Ryan; Ana I Robles; Curtis C Harris
Journal:  Nat Rev Cancer       Date:  2010-06       Impact factor: 60.716

6.  Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

Authors:  Laura Y McGirt; Peilin Jia; Devin A Baerenwald; Robert J Duszynski; Kimberly B Dahlman; John A Zic; Jeffrey P Zwerner; Donald Hucks; Utpal Dave; Zhongming Zhao; Christine M Eischen
Journal:  Blood       Date:  2015-06-16       Impact factor: 22.113

Review 7.  Biomarker development in the precision medicine era: lung cancer as a case study.

Authors:  Ashley J Vargas; Curtis C Harris
Journal:  Nat Rev Cancer       Date:  2016-07-08       Impact factor: 60.716

8.  Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations.

Authors:  Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald Dematteo; Lawrence S Engel
Journal:  Clin Sarcoma Res       Date:  2013-10-26

9.  XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk.

Authors:  Xi Dai Long; Yun Ma; Yun Feng Zhou; Jin Guang Yao; Fu Zhi Ban; Yong Zhi Huang; Bing Cheng Huang
Journal:  BMC Cancer       Date:  2009-11-17       Impact factor: 4.430

10.  Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.

Authors:  Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.